✨
AI Summary
- Dr. Mike Ehlers discusses Ascidian Therapeutics' RNA exon editing for genetic diseases.
- Focus on durably correcting disease at the transcript level without DNA alteration.
- In vivo therapies must prove precision, durability, and predictability in clinic.
Guests on This Episode
ME
Mike Ehlers
1 podcast appearance